Exact Sciences up 14% premarket

|By:, SA News Editor

Shares of Exact Sciences (EXAS) are poised for an opening up move after yesterday's inadvertent posting of clinical trial results for Cologuard.

Compared to colonoscopy, the test was 92% sensitive for cancer stages I & II and 69% for precancerous polyps containing high-grade dysplasia (highest cancer risk).

FDA ad comm to vote on Cologuard March 27.

Consensus revenue estimates for 2014 and 2015 are $22.6M and $98.9M, respectively.

215 mutual funds have positions, up from 185 a year earlier.